According to the National Heart, Lung, and Blood Institute, heart failure is no longer just a disease--it is becoming an epidemic. Today, it is the leading cause of hospitalization in the US and the leading source of health care spending. I happen to have found the right stock to wager on in this multi-billion dollar industry.
Congestive Heart Failure (CHF) is classified into four classes. Class I and II are more »
According to John Burbank, “2012 will be a seminal one for Thoratec.” This medical device manufacturer’s main product is HeartMate II (HM II), a left-ventricular assist device (LVAD). HM II has received its FDA approval for both bridge-to-transplant (BTT) and destination therapy (DT) indications. Thoratec Corp (NASDAQ: THOR) also distributes other short-term circulatory support systems (PVAD, IVAD, and BVAD) and has an extracorporeal short-term circulatory support system called CentriMag more »
By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ
The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.